Figure 6.

Possible outcomes of targeted alpha therapies. Prostate-specific membrane antigen (PSMA)-targeted alpha therapy of metastasized castration-resistant prostate cancer (mCRPC) was selected as an example for the schematic representation of three main hypothetical scenarios. These are (a) full and long-lasting remission, (b) disease recurrence after the successful outcome of the initial therapy, and (c) disease progression, which occurs in spite of the applied therapy (therapy resistance). In addition, possible early and late side effects, such as salivary gland, kidney, and bladder damage, are also indicated in the figure. TAT is usually applied as a third-line or salvage therapy when all other previous treatment options have failed.